Abstract
Autonomic disturbances in Parkinson’s disease (PD) are relatively modest compared with the disorders seen in multiple system atrophy. However, autonomic disorders in PD can lead to serious problems such as sudden death caused by cardiovascular disturbances or malignant syndrome developed following abrupt interruption of dopaminergic medications. The major autonomic disturbances in PD include constipation (Edwards et al., 1993), imparied thermoregulation (Goets et al., 1986), orthostatic hypotension (McTavish and Goa, 1989) and urinary problems (Stocchi et al., 1997). First, the management of these autonomic disorders will be described briefly below. For the detail of the treatment guidelines the reader may wish to consult an excellent review by Olanow and Koller (1998).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Caroff, S. N. and Mann, S. C., 1988, Neuroleptic malignant syndrome, Psychopharmacol Bull 24:25.
Edwards, L. L., Quigley, E. M. M., Hofman, R., and Pfeiffer, R. F., 1993, Gastrointestinal symptoms in Parkinson’s disease: 18-month follow-up study, Mov Disord 8:83.
Goets, C. G., Lutge, W., and Tanner, C. M., 1986, Autonomic dysfunction in Parkinson’s disease, Neurology 36:73.
Henderson, V. W., and Wooten, G. F., 1981, Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade? Neurology 31:132.
Kuno, S., Mizuta, S., and Yamasaki, S., 1997, Neuroleptic malignant syndrome in parkinsonian patients: Risk factors, Eur Neurol 38 (Suppl 2):56.
McTavish, D., and Goa, K. L. 1989, Midodrine, a review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders, Drugs 38: 757.
Mizuta, E., Yamasaki, S., Nakatake, M., and Kuno, S., 1993, Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period, Neurology 43:1048.
Olanow, C. W., and Koller. W. C., 1998, An algorithm (decision tree) for the management of Parkinson’s disease: Treatment guidelines, Neurology 50 (Suppl 3):S1.
Stocchi, F., Carbone, A., Inghilleri, M., Monge, A., Ruggieri, S., Beradelli, A., and Manfredi, M., 1997, Urodynamic and neurophysiological evaluation in Parkinson’s disease and mutiple system atrophy, J Neurol Neurosurg Psychiatry 62:507.
Toru, M., Matsuda, O., Makiguchi, K., and Sugano, K., 1981, Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs, J Nerv Ment Dis 169:324.
Yoshimura, N., Mizuta, E., Yoshida, O., and Kuno, S., 1998, Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys, J Pharmacol exp Therap 286:228.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic / Plenum Publishers, New York
About this chapter
Cite this chapter
Kuno, S. (2002). Autonomic Disorders and Malignant Syndrome in Parkinson’s Disease. In: Mizuno, Y., Fisher, A., Hanin, I. (eds) Mapping the Progress of Alzheimer’s and Parkinson’s Disease. Advances in Behavioral Biology, vol 51. Springer, Boston, MA. https://doi.org/10.1007/978-0-306-47593-1_60
Download citation
DOI: https://doi.org/10.1007/978-0-306-47593-1_60
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0973-5
Online ISBN: 978-0-306-47593-1
eBook Packages: Springer Book Archive